950 Stock Overview An investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Lee's Pharmaceutical Holdings Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Lee's Pharmaceutical Holdings Historical stock prices Current Share Price HK$1.39 52 Week High HK$1.60 52 Week Low HK$1.00 Beta 0.85 1 Month Change 13.01% 3 Month Change 17.80% 1 Year Change -7.33% 3 Year Change -57.23% 5 Year Change -67.37% Change since IPO 167.31%
Recent News & Updates See more updates
Investor sentiment improves as stock rises 16% Dec 12
Investor sentiment improves as stock rises 16% Oct 02
Board Member recently bought HK$66k worth of stock Sep 22
Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem Sep 04
First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023) Sep 03
First half dividend of HK$0.02 announced Aug 30
Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 16
There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price Aug 07
Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong Aug 02
Board Member recently bought HK$59k worth of stock Jul 17
Board Member recently bought HK$117k worth of stock Jul 07
Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director Jul 02
Board Member recently bought HK$120k worth of stock Jun 21
Board Member recently bought HK$61k worth of stock Jun 15
Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01 May 21
Upcoming dividend of HK$0.01 per share May 21
Board Member recently bought HK$130k worth of stock May 10
Less than half of directors are independent Apr 22
Final dividend of HK$0.01 announced Mar 28
Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024 Mar 27
Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022) Mar 27
Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024 Mar 26
Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Mar 15
Board Member recently bought HK$123k worth of stock Jan 25
New minor risk - Market cap size Jan 17
Board Member recently bought HK$75k worth of stock Jan 17
Investor sentiment improves as stock rises 15% Dec 20
Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking Dec 20
Investor sentiment improves as stock rises 18% Nov 30
Board Member recently bought HK$50k worth of stock Nov 29
Board Member recently bought HK$113k worth of stock Oct 31
Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock Oct 06
Investor sentiment improves as stock rises 17% Oct 05
Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock Sep 26
Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock Sep 16
Investor sentiment improves as stock rises 18% Sep 14
Price target decreased by 55% to HK$1.10 Sep 02
Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023 Aug 31
First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022) Aug 31
New minor risk - Market cap size Aug 24 Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023
Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023 Aug 19
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01 May 21
Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director May 18
Upcoming dividend of HK$0.01 per share at 1.3% yield May 18
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01 Apr 02
Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021) Mar 31
Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List Jan 20
Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021) Nov 18
Price target decreased to HK$1.80 Nov 16
Less than half of directors are independent Nov 16
Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022 Nov 05
Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa Oct 27
Price target decreased to HK$1.80 Oct 11
Upcoming dividend of HK$0.01 per share Sep 01
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01 Aug 29
Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022 Aug 27
Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021) Aug 27
Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022 Aug 17
Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022 Aug 16
Board Member recently bought HK$231k worth of stock Jul 21
Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate Jun 22
Board Member recently bought HK$381k worth of stock Jun 10
First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021) May 27
Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate May 20
Upcoming dividend of HK$0.031 per share May 19
Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022 May 17
Price target decreased to HK$4.85 Apr 27
Less than half of directors are independent Apr 27 Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022 Mar 31
Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020) Mar 30 Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022
Price target decreased to HK$5.30 Jan 19
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Nov 26
Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation Sep 29
Second quarter 2021 earnings released: EPS HK$3.59 (vs HK$0.097 in 2Q 2020) Aug 27
Investor sentiment deteriorated over the past week Jul 27
Non-Executive Director Simon Miles Ball has left the company Jul 13
Price target decreased to HK$6.42 Jul 06
First quarter 2021 earnings released: EPS HK$0.07 (vs HK$0.068 in 1Q 2020) May 28
Price target decreased to HK$6.92 May 25
Upcoming dividend of HK$0.031 per share May 24
Lee's Pharmaceutical Holdings Limited Announces Sodium Phenylbutyrate Granules Obtained Approval for Drug Registration May 22
Full year 2020 earnings released: EPS HK$0.22 (vs HK$0.21 in FY 2019) Apr 24
Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet? Apr 05
Full year 2020 earnings released: EPS HK$0.22 (vs HK$0.21 in FY 2019) Mar 31
Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021 Mar 19
Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum? Mar 17
Investor sentiment improved over the past week Mar 16
Lee's Pharmaceutical Holdings Limited Provides Update on an Investigational Direct Oral Anticoagulant Mar 13
Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend? Feb 22
Investor sentiment improved over the past week Feb 10
New 90-day high: HK$6.01 Feb 09
What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago? Jan 29
New 90-day high: HK$5.25 Jan 21 Shareholder Returns 950 HK Pharmaceuticals HK Market 7D 0.7% -1.9% -0.5% 1Y -7.3% -3.9% 19.9%
See full shareholder returns
Return vs Market: 950 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility Is 950's price volatile compared to industry and market? 950 volatility 950 Average Weekly Movement 7.7% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Stable Share Price: 950 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 950's weekly volatility (8%) has been stable over the past year.
About the Company Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. It focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates through Proprietary and Generic Products; and Licensed-In Products segments.
Show more Lee's Pharmaceutical Holdings Limited Fundamentals Summary How do Lee's Pharmaceutical Holdings's earnings and revenue compare to its market cap? 950 fundamental statistics Market cap HK$818.48m Earnings (TTM ) HK$63.06m Revenue (TTM ) HK$1.20b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 950 income statement (TTM ) Revenue HK$1.20b Cost of Revenue HK$581.63m Gross Profit HK$617.44m Other Expenses HK$554.38m Earnings HK$63.06m
Dividends
2.2% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 01:57 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lee's Pharmaceutical Holdings Limited is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Cheng 3V Capital Limited Yue-Kwong Lui BOCOM International Securities Limited Chu Wang Citigroup Inc
Show 6 more analysts 
